Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Richard Thomas Penson, M.B.,B.S.

Title
Institution
Department
Address
Phone
Fax

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Konstantinopoulos PA, Cheng SC, Wahner Hendrickson AE, Penson RT, Schumer ST, Doyle LA, Lee EK, Kohn EC, Duska LR, Crispens MA, Olawaiye AB, Winer IS, Barroilhet LM, Fu S, McHale MT, Schilder RJ, Färkkilä A, Chowdhury D, Curtis J, Quinn RS, Bowes B, D'Andrea AD, Shapiro GI, Matulonis UA. Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2020 07; 21(7):957-968. PMID: 32553118.
    Citations:    
  2. Penson RT, Lowe ES. Reply to E. Paulino et al. J Clin Oncol. 2020 Jun 12; JCO2001235. PMID: 32530766.
    Citations:    
  3. Penson RT. Platinum-sensitive ovarian cancer: liminal advances. Lancet Oncol. 2020 05; 21(5):614-615. PMID: 32305100.
    Citations:    
  4. Arend RC, Beer HM, Cohen YC, Berlin S, Birrer MJ, Campos SM, Rachmilewitz Minei T, Harats D, Wall JA, Foxall ME, Penson RT. Ofranergene obadenovec (VB-111) in platinum-resistant ovarian cancer; favorable response rates in a phase I/II study are associated with an immunotherapeutic effect. Gynecol Oncol. 2020 Jun; 157(3):578-584. PMID: 32265057.
    Citations:    
  5. Chase D, Huang HQ, Monk BJ, Ramondetta LM, Penson RT, Gil K, Landrum LM, Leitao M, Oaknin A, Huh WK, Pulaski HL, Robison K, Guntupalli SR, Richardson D, Salani R, Sill MW, Wenzel LB, Tewari KS. Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study. Int J Gynecol Cancer. 2020 May; 30(5):596-601. PMID: 32114513.
    Citations:    
  6. Penson RT, Valencia RV, Cibula D, Colombo N, Leath CA, Bidzinski M, Kim JW, Nam JH, Madry R, Hernández C, Mora PAR, Ryu SY, Milenkova T, Lowe ES, Barker L, Scambia G. Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial. J Clin Oncol. 2020 Apr 10; 38(11):1164-1174. PMID: 32073956.
    Citations:    
  7. O'Malley DM, Matulonis UA, Birrer MJ, Castro CM, Gilbert L, Vergote I, Martin LP, Mantia-Smaldone GM, Martin AG, Bratos R, Penson RT, Malek K, Moore KN. Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer. Gynecol Oncol. 2020 May; 157(2):379-385. PMID: 32081463.
    Citations:    
  8. Vergote I, Powell MA, Teneriello MG, Miller DS, Garcia AA, Mikheeva ON, Bidzinski M, Cebotaru CL, Dutcus CE, Ren M, Kadowaki T, Funahashi Y, Penson RT. Second-line lenvatinib in patients with recurrent endometrial cancer. Gynecol Oncol. 2020 03; 156(3):575-582. PMID: 31955859.
    Citations:    
  9. Nitecki R, Bercow AS, Gockley AA, Lee H, Penson RT, Growdon WB. Clinical trial participation and aggressive care at the end of life in patients with ovarian cancer. Int J Gynecol Cancer. 2020 02; 30(2):201-206. PMID: 31911533.
    Citations:    
  10. Liu JF, Herold C, Gray KP, Penson RT, Horowitz N, Konstantinopoulos PA, Castro CM, Hill SJ, Curtis J, Luo W, Matulonis UA, Cannistra SA, Dizon DS. Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial. JAMA Oncol. 2019 Oct 10. PMID: 31600397.
    Citations:    
  11. Konstantinopoulos PA, Luo W, Liu JF, Gulhan DC, Krasner C, Ishizuka JJ, Gockley AA, Buss M, Growdon WB, Crowe H, Campos S, Lindeman NI, Hill S, Stover E, Schumer S, Wright AA, Curtis J, Quinn R, Whalen C, Gray KP, Penson RT, Cannistra SA, Fleming GF, Matulonis UA. Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer. J Clin Oncol. 2019 10 20; 37(30):2786-2794. PMID: 31461377.
    Citations:    
  12. Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, Berek JS, Chen LM, Cristea M, DeRosa M, ElNaggar AC, Gershenson DM, Gray HJ, Hakam A, Jain A, Johnston C, Leath CA, Liu J, Mahdi H, Matei D, McHale M, McLean K, O'Malley DM, Penson RT, Percac-Lima S, Ratner E, Remmenga SW, Sabbatini P, Werner TL, Zsiros E, Burns JL, Engh AM. NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019. J Natl Compr Canc Netw. 2019 08 01; 17(8):896-909. PMID: 31390583.
    Citations:    
  13. Zeng Y, Li B, Li T, Liu W, Ran C, Penson RT, Poznansky MC, Du Y, Chen H. CD90low MSCs modulate intratumoral immunity to confer antitumor activity in a mouse model of ovarian cancer. Oncotarget. 2019 Jul 08; 10(43):4479-4491. PMID: 31320999.
    Citations:    
  14. Konstantinopoulos PA, Waggoner S, Vidal GA, Mita M, Moroney JW, Holloway R, Van Le L, Sachdev JC, Chapman-Davis E, Colon-Otero G, Penson RT, Matulonis UA, Kim YB, Moore KN, Swisher EM, Färkkilä A, D'Andrea A, Stringer-Reasor E, Wang J, Buerstatte N, Arora S, Graham JR, Bobilev D, Dezube BJ, Munster P. Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma. JAMA Oncol. 2019 Jun 13. PMID: 31194228.
    Citations:    
  15. Gore M, Hackshaw A, Brady WE, Penson RT, Zaino R, McCluggage WG, Ganesan R, Wilkinson N, Perren T, Montes A, Summers J, Lord R, Dark G, Rustin G, Mackean M, Reed N, Kehoe S, Frumovitz M, Christensen H, Feeney A, Ledermann J, Gershenson DM. An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor. Gynecol Oncol. 2019 06; 153(3):541-548. PMID: 31005287.
    Citations:    
  16. Krasner CN, Castro C, Penson RT, Roche M, Matulonis UA, Morgan MA, Drescher C, Armstrong DK, Wolfe JK, Lee H, Supko JG, Seiden M, Birrer MJ, Dizon DS. Final report on serial phase II trials of all-intraperitoneal chemotherapy with or without bevacizumab for women with newly diagnosed, optimally cytoreduced carcinoma of Müllerian origin. Gynecol Oncol. 2019 05; 153(2):223-229. PMID: 30765148.
    Citations:    
  17. McGuire WP, Penson RT, Gore M, Herraez AC, Peterson P, Shahir A, Ilaria R. Randomized phase II study of the PDGFRa antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer. BMC Cancer. 2018 Dec 27; 18(1):1292. PMID: 30591028.
    Citations:    Fields:    
  18. Friedlander M, Gebski V, Gibbs E, Davies L, Bloomfield R, Hilpert F, Wenzel LB, Eek D, Rodrigues M, Clamp A, Penson RT, Provencher D, Korach J, Huzarski T, Vidal L, Salutari V, Scott C, Nicoletto MO, Tamura K, Espinoza D, Joly F, Pujade-Lauraine E. Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial. Lancet Oncol. 2018 08; 19(8):1126-1134. PMID: 30026002.
    Citations:    Fields:    
  19. Volpe J, Filipi JG, Cooper OR, Penson RT. Frontline therapy of ovarian cancer: trials and tribulations. Curr Opin Obstet Gynecol. 2018 Feb; 30(1):1-6. PMID: 29251676.
    Citations:    Fields:    Translation:Humans
  20. Seamon LG, Java JJ, Monk BJ, Penson RT, Brown J, Mannel RS, Oaknin A, Leitao MM, Eisenhauer EL, Long HJ, Liao SY, Tewari KS. Impact of tumour histology on survival in advanced cervical carcinoma: an NRG Oncology/Gynaecologic Oncology Group Study. Br J Cancer. 2018 01; 118(2):162-170. PMID: 29182608.
    Citations:    Fields:    Translation:Humans
  21. Tewari KS, Sill MW, Penson RT, Huang H, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Michael HE, DiSaia PJ, Copeland LJ, Creasman WT, Stehman FB, Brady MF, Burger RA, Thigpen JT, Birrer MJ, Waggoner SE, Moore DH, Look KY, Koh WJ, Monk BJ. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet. 2017 Oct 07; 390(10103):1654-1663. PMID: 28756902.
    Citations: 5     Fields:    Translation:HumansCTClinical Trials
  22. Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, Korach J, Huzarski T, Poveda A, Pignata S, Friedlander M, Colombo N, Harter P, Fujiwara K, Ray-Coquard I, Banerjee S, Liu J, Lowe ES, Bloomfield R, Pautier P. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017 09; 18(9):1274-1284. PMID: 28754483.
    Citations: 33     Fields:    Translation:HumansCTClinical Trials
  23. Wenzel LB, Ward S, Sereika SM, Edwards RP, Spring M, Bender CM, Penson RT, Hagan T. Determining priority symptoms of women with recurrent ovarian cancers: A Gynecologic Oncology Group study. J Clin Oncol. 2016 Oct 09; 34(26_suppl):101. PMID: 28156639.
    Citations:    
  24. Lax T, Dizon DS, Birrer M, Long A, Del Carmen M, Goodman A, Krasner C, Penson RT, Growdon W, Camargo CA, Banerji A. Extended carboplatin infusion does not reduce frequency of hypersensitivity reaction at initiation of retreatment in patients with recurrent platinum-sensitive ovarian cancer. J Allergy Clin Immunol Pract. 2017 Jan - Feb; 5(1):177-178. PMID: 27641482.
    Citations: 3     Fields:    Translation:Humans
  25. Morgan RJ, Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Behbakht K, Chen LM, Copeland L, Crispens MA, DeRosa M, Dorigo O, Gershenson DM, Gray HJ, Hakam A, Havrilesky LJ, Johnston C, Lele S, Martin L, Matulonis UA, O'Malley DM, Penson RT, Percac-Lima S, Pineda M, Plaxe SC, Powell MA, Ratner E, Remmenga SW, Rose PG, Sabbatini P, Santoso JT, Werner TL, Burns J, Hughes M. Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016 09; 14(9):1134-63. PMID: 27587625.
    Citations: 28     Fields:    Translation:Humans
  26. Penson RT, Sales E, Sullivan L, Borger DR, Krasner CN, Goodman AK, del Carmen MG, Growdon WB, Schorge JO, Boruta DM, Castro CM, Dizon DS, Birrer MJ. A SNaPshot of potentially personalized care: Molecular diagnostics in gynecologic cancer. Gynecol Oncol. 2016 Apr; 141(1):108-12. PMID: 27016236.
    Citations:    Fields:    Translation:Humans
  27. Matulonis UA, Penson RT, Domchek SM, Kaufman B, Shapira-Frommer R, Audeh MW, Kaye S, Molife LR, Gelmon KA, Robertson JD, Mann H, Ho TW, Coleman RL. Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety. Ann Oncol. 2016 06; 27(6):1013-9. PMID: 26961146.
    Citations: 19     Fields:    Translation:Humans
  28. Chan JK, Brady MF, Penson RT, Huang H, Birrer MJ, Walker JL, DiSilvestro PA, Rubin SC, Martin LP, Davidson SA, Huh WK, O'Malley DM, Boente MP, Michael H, Monk BJ. Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer. N Engl J Med. 2016 Feb 25; 374(8):738-48. PMID: 26933849.
    Citations: 26     Fields:    Translation:HumansCTClinical Trials
  29. Tewari KS, Sill MW, Monk BJ, Penson RT, Long HJ, Poveda A, Landrum LM, Leitao MM, Brown J, Reid TJ, Michael HE, Moore DH. Prospective Validation of Pooled Prognostic Factors in Women with Advanced Cervical Cancer Treated with Chemotherapy with/without Bevacizumab: NRG Oncology/GOG Study. Clin Cancer Res. 2015 Dec 15; 21(24):5480-7. PMID: 26672085.
    Citations: 7     Fields:    Translation:HumansCTClinical Trials
  30. Scalia-Wilbur J, Colins BL, Penson RT, Dizon DS. Breast Cancer Risk Assessment: Moving Beyond BRCA 1 and 2. Semin Radiat Oncol. 2016 Jan; 26(1):3-8. PMID: 26617204.
    Citations: 2     Fields:    Translation:Humans
  31. Kronish DP, Penson RT. Theorist's Toy: Equipoise. J Natl Compr Canc Netw. 2015 Jul; 13(7):936-8. PMID: 26150585.
    Citations:    Fields:    Translation:Humans
  32. Matulonis U, Berlin S, Lee H, Whalen C, Obermayer E, Penson R, Liu J, Campos S, Krasner C, Horowitz N. Phase I study of combination of vorinostat, carboplatin, and gemcitabine in women with recurrent, platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer. Cancer Chemother Pharmacol. 2015 Aug; 76(2):417-23. PMID: 26119093.
    Citations: 8     Fields:    Translation:HumansCTClinical Trials
  33. Penson RT, Huang HQ, Wenzel LB, Monk BJ, Stockman S, Long HJ, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Method M, Michael H, Tewari KS. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240). Lancet Oncol. 2015 Mar; 16(3):301-11. PMID: 25638326.
    Citations: 22     Fields:    Translation:HumansCTClinical Trials
  34. Schorge JO, Clark RM, Lee SI, Penson RT. Primary debulking surgery for advanced ovarian cancer: are you a believer or a dissenter? Gynecol Oncol. 2014 Dec; 135(3):595-605. PMID: 25316177.
    Citations: 10     Fields:    Translation:Humans
  35. Penson RT, Moore KM, Fleming GF, Braly P, Schimp V, Nguyen H, Matulonis UA, Banerjee S, Haluska P, Gore M, Bodurka DC, Hozak RR, Joshi A, Xu Y, Schwartz JD, McGuire WP. A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma. Gynecol Oncol. 2014 Sep; 134(3):478-85. PMID: 25016924.
    Citations: 5     Fields:    Translation:HumansCTClinical Trials
  36. Donovan KA, Donovan HS, Cella D, Gaines ME, Penson RT, Plaxe SC, von Gruenigen VE, Bruner DW, Reeve BB, Wenzel L. Recommended patient-reported core set of symptoms and quality-of-life domains to measure in ovarian cancer treatment trials. J Natl Cancer Inst. 2014 Jul; 106(7). PMID: 25006190.
    Citations: 8     Fields:    Translation:Humans
  37. Ambrosio AJ, Suzin D, Palmer EL, Penson RT. Vintafolide (EC145) for the treatment of folate-receptor-a positive platinum-resistant ovarian cancer. Expert Rev Clin Pharmacol. 2014 Jul; 7(4):443-50. PMID: 24742319.
    Citations: 3     Fields:    Translation:Humans
  38. Schapira L, Blaszkowsky LS, Cashavelly BJ, Kim CY, Riley JP, Wold MC, Ryan DP, Penson RT. Caring for one of our own. Oncologist. 2014 May; 19(5):545-9. PMID: 24721818.
    Citations: 3     Fields:    Translation:Humans
  39. Tewari KS, Sill MW, Long HJ, Penson RT, Huang H, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Michael HE, Monk BJ. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014 Feb 20; 370(8):734-43. PMID: 24552320.
    Citations: 202     Fields:    Translation:HumansCTClinical Trials
  40. Peterson VM, Castro CM, Chung J, Miller NC, Ullal AV, Castano MD, Penson RT, Lee H, Birrer MJ, Weissleder R. Ascites analysis by a microfluidic chip allows tumor-cell profiling. Proc Natl Acad Sci U S A. 2013 Dec 17; 110(51):E4978-86. PMID: 24297935.
    Citations: 14     Fields:    Translation:HumansCTClinical Trials
  41. George S, Feng Y, Manola J, Nucci MR, Butrynski JE, Morgan JA, Ramaiya N, Quek R, Penson RT, Wagner AJ, Harmon D, Demetri GD, Krasner C. Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcomas expressing estrogen and/or progesterone receptors. Cancer. 2014 Mar 01; 120(5):738-43. PMID: 24222211.
    Citations: 14     Fields:    Translation:HumansCTClinical Trials
  42. Naumann RW, Coleman RL, Burger RA, Sausville EA, Kutarska E, Ghamande SA, Gabrail NY, Depasquale SE, Nowara E, Gilbert L, Gersh RH, Teneriello MG, Harb WA, Konstantinopoulos PA, Penson RT, Symanowski JT, Lovejoy CD, Leamon CP, Morgenstern DE, Messmann RA. PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2013 Dec 10; 31(35):4400-6. PMID: 24127448.
    Citations: 52     Fields:    Translation:HumansCTClinical Trials
  43. Morgan RJ, Alvarez RD, Armstrong DK, Burger RA, Chen LM, Copeland L, Crispens MA, Gershenson DM, Gray HJ, Hakam A, Havrilesky LJ, Johnston C, Lele S, Martin L, Matulonis UA, O'Malley DM, Penson RT, Powell MA, Remmenga SW, Sabbatini P, Santoso JT, Schink JC, Teng N, Werner TL, Dwyer MA, Hughes M. Ovarian cancer, version 2.2013. J Natl Compr Canc Netw. 2013 Oct 01; 11(10):1199-209. PMID: 24142821.
    Citations: 30     Fields:    Translation:Humans
  44. Penson RT, Dizon DS, Birrer MJ. Clear cell cancer of the ovary. Curr Opin Oncol. 2013 Sep; 25(5):553-7. PMID: 23942300.
    Citations: 7     Fields:    Translation:Humans
  45. Penson RT, Goodman A, Growdon WB, Borger DR, Lee SI, Oliva E. Case records of the Massachusetts General Hospital. Case 14-2013. A 70-year-old woman with vaginal bleeding. N Engl J Med. 2013 May 09; 368(19):1827-35. PMID: 23656649.
    Citations:    Fields:    Translation:Humans
  46. Penson RT. Complexions of compliance. Menopause. 2013 Jan; 20(1):3-4. PMID: 23266837.
    Citations:    Fields:    Translation:Humans
  47. Lu W, Matulonis UA, Dunn JE, Lee H, Doherty-Gilman A, Dean-Clower E, Goodman A, Davis RB, Buring J, Wayne P, Rosenthal DS, Penson RT. The Feasibility and Effects of Acupuncture on Quality of Life Scores During Chemotherapy in Ovarian Cancer: Results from a Pilot, Randomized Sham-Controlled Trial. Med Acupunct. 2012 12; 24(4):233-240. PMID: 24761165.
    Citations: 1     
  48. Morgan RJ, Alvarez RD, Armstrong DK, Burger RA, Castells M, Chen LM, Copeland L, Crispens MA, Gershenson D, Gray H, Hakam A, Havrilesky LJ, Johnston C, Lele S, Martin L, Matulonis UA, O'Malley DM, Penson RT, Remmenga SW, Sabbatini P, Santoso JT, Schilder RJ, Schink J, Teng N, Werner TL, Hughes M, Dwyer MA. Ovarian cancer, version 3.2012. J Natl Compr Canc Netw. 2012 Nov 01; 10(11):1339-49. PMID: 23138163.
    Citations: 19     Fields:    Translation:Humans
  49. Campos SM, Penson RT, Matulonis U, Horowitz NS, Whalen C, Pereira L, Tyburski K, Roche M, Szymonifka J, Berlin S. A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma. Gynecol Oncol. 2013 Feb; 128(2):215-20. PMID: 22885865.
    Citations: 13     Fields:    Translation:HumansCTClinical Trials
  50. Dizon DS, Damstrup L, Finkler NJ, Lassen U, Celano P, Glasspool R, Crowley E, Lichenstein HS, Knoblach P, Penson RT. Phase II activity of belinostat (PXD-101), carboplatin, and paclitaxel in women with previously treated ovarian cancer. Int J Gynecol Cancer. 2012 Jul; 22(6):979-86. PMID: 22694911.
    Citations: 16     Fields:    Translation:HumansCTClinical Trials
  51. Girouard SD, Velez NF, Penson RT, Massarotti EM, Vleugels RA. Panniculitis associated with dermatomyositis and recurrent ovarian cancer. Arch Dermatol. 2012 Jun; 148(6):740-4. PMID: 22431715.
    Citations: 3     Fields:    Translation:Humans
  52. Dizon DS, Blessing JA, Penson RT, Drake RD, Walker JL, Johnston CM, Disilvestro PA, Fader AN. A phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 May; 125(2):367-71. PMID: 22366594.
    Citations: 14     Fields:    Translation:HumansCTClinical Trials
  53. Carter J, Penson R, Barakat R, Wenzel L. Contemporary quality of life issues affecting gynecologic cancer survivors. Hematol Oncol Clin North Am. 2012 Feb; 26(1):169-94. PMID: 22244668.
    Citations: 4     Fields:    Translation:Humans
  54. Lai GG, Penson RT. Bevacizumab and ovarian cancer. Drugs Today (Barc). 2011 Sep; 47(9):669-81. PMID: 21971541.
    Citations: 2     Fields:    Translation:HumansAnimals
  55. Horowitz NS, Penson RT, Duda DG, di Tomaso E, Boucher Y, Ancukiewicz M, Cohen KS, Berlin S, Krasner CN, Moses MA, Jain RK. Safety, Efficacy, and Biomarker Exploration in a Phase II Study of Bevacizumab, Oxaliplatin, and Gemcitabine in Recurrent Müllerian Carcinoma. Clin Ovarian Cancer Other Gynecol Malig. 2011 Jun; 4(1):26-33. PMID: 21833345.
    Citations: 8     
  56. Liu J, Fleming GF, Tolaney SM, Birrer MJ, Penson RT, Berlin ST, Whalen C, Tyburski K, Matijevich K, Kasparian E, Roche M, Lee H, Winer EP, Ivy SP, Matulonis U. A phase I trial of the PARP inhibitor olaparib (AZD2281) in combination with the antiangiogenic cediranib (AZD2171) in recurrent ovarian or triple-negative breast cancer. J Clin Oncol. 2011 May 20; 29(15_suppl):5028. PMID: 28023743.
    Citations:    
  57. Birrer MJ, Konstantinopoulos P, Penson RT, Roche M, Ambrosio A, Stallings TE, Matulonis U, Bradley CR. A phase II trial of iniparib (BSI-201) in combination with gemcitabine/carboplatin (GC) in patients with platinum-resistant recurrent ovarian cancer. J Clin Oncol. 2011 May 20; 29(15_suppl):5005. PMID: 28023775.
    Citations:    
  58. Penson RT, Whalen C, Lasonde B, Krasner CN, Konstantinopoulos P, Stallings TE, Bradley CR, Birrer MJ, Matulonis U. A phase II trial of iniparib (BSI-201) in combination with gemcitabine/carboplatin (GC) in patients with platinum-sensitive recurrent ovarian cancer. J Clin Oncol. 2011 May 20; 29(15_suppl):5004. PMID: 28023776.
    Citations:    
  59. Armstrong DK, Coleman RL, Penson RT. Emerging therapeutic options for platinum-sensitive ovarian cancer patients. Clin Adv Hematol Oncol. 2011 Apr; 9(4 Suppl 5):1-16. PMID: 21558997.
    Citations:    Fields:    Translation:Humans
  60. Bell-McGuinn KM, Matthews CM, Ho SN, Barve M, Gilbert L, Penson RT, Lengyel E, Palaparthy R, Gilder K, Vassos A, McAuliffe W, Weymer S, Barton J, Schilder RJ. A phase II, single-arm study of the anti-a5ß1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer. Gynecol Oncol. 2011 May 01; 121(2):273-9. PMID: 21276608.
    Citations: 34     Fields:    Translation:HumansCellsCTClinical Trials
  61. Morgan RJ, Alvarez RD, Armstrong DK, Boston B, Burger RA, Chen LM, Copeland L, Crispens MA, Gershenson D, Gray HJ, Grigsby PW, Hakam A, Havrilesky LJ, Johnston C, Lele S, Matulonis UA, O'Malley DM, Penson RT, Remmenga SW, Sabbatini P, Schilder RJ, Schink JC, Teng N, Werner TL. Epithelial ovarian cancer. J Natl Compr Canc Netw. 2011 Jan; 9(1):82-113. PMID: 21233246.
    Citations: 27     Fields:    Translation:Humans
  62. Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, Scott C, Weitzel JN, Oaknin A, Loman N, Lu K, Schmutzler RK, Matulonis U, Wickens M, Tutt A. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet. 2010 Jul 24; 376(9737):245-51. PMID: 20609468.
    Citations: 385     Fields:    Translation:HumansCTClinical Trials
  63. Penson RT, Schapira L, Mack S, Stanzler M, Lynch TJ. Connection: Schwartz Center Rounds at Massachusetts General Hospital Cancer Center. Oncologist. 2010; 15(7):760-4. PMID: 20584809.
    Citations: 1     Fields:    Translation:Humans
  64. Lassen U, Molife LR, Sorensen M, Engelholm SA, Vidal L, Sinha R, Penson RT, Buhl-Jensen P, Crowley E, Tjornelund J, Knoblauch P, de Bono JS. A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours. Br J Cancer. 2010 Jun 29; 103(1):12-7. PMID: 20588278.
    Citations: 19     Fields:    Translation:HumansCTClinical Trials
  65. Dean-Clower E, Doherty-Gilman AM, Keshaviah A, Baker F, Kaw C, Lu W, Manola J, Penson RT, Matulonis UA, Rosenthal DS. Acupuncture as palliative therapy for physical symptoms and quality of life for advanced cancer patients. Integr Cancer Ther. 2010 Jun; 9(2):158-67. PMID: 20483875.
    Citations: 16     Fields:    Translation:Humans
  66. Young RH, Goodman A, Penson RT, Russell AH, Uppot RN, Tambouret RH. Case records of the Massachusetts General Hospital. Case 8-2010. A 22-year-old woman with hypercalcemia and a pelvic mass. N Engl J Med. 2010 Mar 18; 362(11):1031-40. PMID: 20237350.
    Citations: 4     Fields:    Translation:Humans
  67. Robinson ES, Matulonis UA, Ivy P, Berlin ST, Tyburski K, Penson RT, Humphreys BD. Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor. Clin J Am Soc Nephrol. 2010 Mar; 5(3):477-83. PMID: 20056761.
    Citations: 24     Fields:    Translation:HumansCTClinical Trials
  68. Kornblith AB, Mirabeau-Beale K, Lee H, Goodman AK, Penson RT, Pereira L, Matulonis UA. Long-term adjustment of survivors of ovarian cancer treated for advanced-stage disease. J Psychosoc Oncol. 2010; 28(5):451-69. PMID: 20730659.
    Citations: 12     Fields:    Translation:Humans
  69. Na YJ, Farley J, Zeh A, del Carmen M, Penson R, Birrer MJ. Ovarian cancer: markers of response. Int J Gynecol Cancer. 2009 Dec; 19 Suppl 2:S21-9. PMID: 19955910.
    Citations: 6     Fields:    Translation:Humans
  70. Roche MR, Rudd PJ, Krasner CN, Matulonis UA, Berlin ST, Lee H, Silver M, Tran CD, Seiden MV, Penson RT. Phase II trial of GM-CSF in women with asymptomatic recurrent müllerian tumors. Gynecol Oncol. 2010 Feb; 116(2):168-72. PMID: 19922985.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  71. Penson RT, Dizon DS, Cannistra SA, Roche MR, Krasner CN, Berlin ST, Horowitz NS, Disilvestro PA, Matulonis UA, Lee H, King MA, Campos SM. Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors. J Clin Oncol. 2010 Jan 01; 28(1):154-9. PMID: 19917843.
    Citations: 29     Fields:    Translation:HumansCTClinical Trials
  72. Matulonis UA, Berlin S, Ivy P, Tyburski K, Krasner C, Zarwan C, Berkenblit A, Campos S, Horowitz N, Cannistra SA, Lee H, Lee J, Roche M, Hill M, Whalen C, Sullivan L, Tran C, Humphreys BD, Penson RT. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol. 2009 Nov 20; 27(33):5601-6. PMID: 19826113.
    Citations: 71     Fields:    Translation:HumansCTClinical Trials
  73. Lu W, Matulonis UA, Doherty-Gilman A, Lee H, Dean-Clower E, Rosulek A, Gibson C, Goodman A, Davis RB, Buring JE, Wayne PM, Rosenthal DS, Penson RT. Acupuncture for chemotherapy-induced neutropenia in patients with gynecologic malignancies: a pilot randomized, sham-controlled clinical trial. J Altern Complement Med. 2009 Jul; 15(7):745-53. PMID: 19552597.
    Citations: 14     Fields:    Translation:Humans
  74. Hesterberg PE, Banerji A, Oren E, Penson RT, Krasner CN, Seiden MV, Wong JT. Risk stratification for desensitization of patients with carboplatin hypersensitivity: clinical presentation and management. J Allergy Clin Immunol. 2009 Jun; 123(6):1262-7.e1. PMID: 19501233.
    Citations: 12     Fields:    Translation:Humans
  75. Mirabeau-Beale KL, Kornblith AB, Penson RT, Lee H, Goodman A, Campos SM, Duska L, Pereira L, Bryan J, Matulonis UA. Comparison of the quality of life of early and advanced stage ovarian cancer survivors. Gynecol Oncol. 2009 Aug; 114(2):353-9. PMID: 19481244.
    Citations: 26     Fields:    Translation:Humans
  76. Audeh MW, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, Scott C, Weitzel JN, Carmichael J, Tutt A. Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer. J Clin Oncol. 2009 May 20; 27(15_suppl):5500. PMID: 27962445.
    Citations:    
  77. Mann P, Schapira L, Lynch T, Penson R. Utility of Schwartz Center Rounds in fostering compassion, communication, teamwork, and caregiver support. J Clin Oncol. 2009 May 20; 27(15_suppl):e20640. PMID: 27961662.
    Citations:    
  78. Koulouris CR, Penson RT. Ovarian stromal and germ cell tumors. Semin Oncol. 2009 Apr; 36(2):126-36. PMID: 19332247.
    Citations: 4     Fields:    Translation:Humans
  79. Penson RT. Sugar fuels cancer. Cancer. 2009 Mar 01; 115(5):918-21. PMID: 19156846.
    Citations:    Fields:    Translation:Humans
  80. Matulonis UA, Krag KJ, Krasner CN, Atkinson T, Horowitz NS, Lee H, Penson RT. Phase II prospective study of paclitaxel and carboplatin in older patients with newly diagnosed Müllerian tumors. Gynecol Oncol. 2009 Feb; 112(2):394-9. PMID: 19058838.
    Citations: 5     Fields:    Translation:HumansCTClinical Trials
  81. Matulonis UA, Horowitz NS, Campos SM, Lee H, Lee J, Krasner CN, Berlin S, Roche MR, Duska LR, Pereira L, Kendall D, Penson RT. Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer. J Clin Oncol. 2008 Dec 10; 26(35):5761-6. PMID: 19001330.
    Citations: 12     Fields:    Translation:HumansCTClinical Trials
  82. Olawaiye AB, Morgan JA, Goodman A, Fuller AF, Penson RT. Epithelioid angiosarcoma of the uterus: a review of management. Arch Gynecol Obstet. 2008 Nov; 278(5):401-4. PMID: 18642010.
    Citations: 8     Fields:    Translation:Humans
  83. Finkler NJ, Dizon DS, Braly P, Micha J, Lassen U, Celano P, Glasspool R, Crowley E, Buhl-Jensen P, Penson RT. Phase II multicenter trial of the histone deactylase inhibitor (HDACi) belinostat, carboplatin and paclitaxel (BelCaP) in patients (pts) with relapsed epithelial ovarian cancer (EOC). J Clin Oncol. 2008 May 20; 26(15_suppl):5519. PMID: 27950857.
    Citations:    
  84. Gross AH, Cromwell J, Kornblith AB, Lee H, Li H, Pereira L, Penson RT, Matulonis UA. Effects of complementary and alternative medicine use on hopelessness in ovarian cancer patients. J Clin Oncol. 2008 May 20; 26(15_suppl):9598. PMID: 27950287.
    Citations:    
  85. Matulonis UA, Berlin ST, Krasner CN, Tyburski K, Lee J, Roche M, Ivy SP, Lenahan C, King M, Penson RT. Cediranib (AZD2171) is an active agent in recurrent epithelial ovarian cancer. J Clin Oncol. 2008 May 20; 26(15_suppl):5501. PMID: 27950813.
    Citations:    
  86. Penson RT, Kornblith AB, Lee J, Roche M, Atkinson T, Gibson CD, Horowitz NS, Krag KJ, Krasner CN, Matulonis UA. Phase II study of carboplatin and paclitaxel in elderly women with newly diagnosed ovarian, peritoneal, or fallopian tube cancer. J Clin Oncol. 2008 May 20; 26(15_suppl):5590. PMID: 27950420.
    Citations:    
  87. Mirabeau-Beale K, Kornblith AB, Penson RT, Lee H, Goodman A, Campos SM, Duska LR, Pereira L, Gibson CD, Matulonis UA. Comparison of the quality of life of early and advanced stage ovarian cancer survivors. J Clin Oncol. 2008 May 20; 26(15_suppl):5528. PMID: 27950848.
    Citations:    
  88. Duda DG, Cohen KS, Ancukiewicz M, di Tomaso E, Zhu AX, Penson RT, Horowitz NS, Batchelor TT, Willett CG, Jain RK. A comparative study of circulating endothelial cells (CECs) and circulating progenitor cells (CPCs) kinetics in four multidisciplinary phase II studies of antiangiogenic agents. J Clin Oncol. 2008 May 20; 26(15_suppl):3544. PMID: 27949773.
    Citations:    
  89. Horowitz NS, Penson RT, Campos SM, Lee J, Kendall DL, Krasner CN, Berlin ST, Roche M, Duska LR, Matulonis UA. Combination carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer. J Clin Oncol. 2008 May 20; 26(15_suppl):5523. PMID: 27950841.
    Citations:    
  90. Krasner CN, Seiden MV, Penson RT, Roche M, Kendall DL, Young J, Matulonis UA, Pereira L, Berlin ST. NOV-002 plus carboplatin in platinum-resistant ovarian cancer. J Clin Oncol. 2008 May 20; 26(15_suppl):5593. PMID: 27950463.
    Citations:    
  91. McGuire WP, Hirte HW, Matulonis UA, Penson RT, Husain A, Hoskins PJ, Michels J, Michelson G, Chiang A, Aghajanian CA. A phase II trial of SNS-595 in women with platinum resistant epithelial ovarian cancer. J Clin Oncol. 2008 May 20; 26(15_suppl):5582. PMID: 27950396.
    Citations:    
  92. Penson RT. Cycles within cycles. Menopause. 2008 May-Jun; 15(3):412-3. PMID: 18391835.
    Citations:    Fields:    Translation:HumansCells
  93. Matulonis UA, Kornblith A, Lee H, Bryan J, Gibson C, Wells C, Lee J, Sullivan L, Penson R. Long-term adjustment of early-stage ovarian cancer survivors. Int J Gynecol Cancer. 2008 Nov-Dec; 18(6):1183-93. PMID: 18217977.
    Citations: 35     Fields:    Translation:Humans
  94. Rauh-Hain JA, Penson RT. Potential benefit of Sunitinib in recurrent and refractory ovarian clear cell adenocarcinoma. Int J Gynecol Cancer. 2008 Sep-Oct; 18(5):934-6. PMID: 18081793.
    Citations: 10     Fields:    Translation:Humans
  95. Cannistra SA, Matulonis UA, Penson RT, Hambleton J, Dupont J, Mackey H, Douglas J, Burger RA, Armstrong D, Wenham R, McGuire W. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol. 2007 Nov 20; 25(33):5180-6. PMID: 18024865.
    Citations: 200     Fields:    Translation:HumansCTClinical Trials
  96. Penson RT, Gu F, Harris S, Thiel MM, Lawton N, Fuller AF, Lynch TJ. Hope. Oncologist. 2007 Sep; 12(9):1105-13. PMID: 17914080.
    Citations: 7     Fields:    Translation:Humans
  97. Abrams AN, Hazen EP, Penson RT. Psychosocial issues in adolescents with cancer. Cancer Treat Rev. 2007 Nov; 33(7):622-30. PMID: 17434265.
    Citations: 24     Fields:    Translation:Humans
  98. Penson RT, Wenzel LB, Vergote I, Cella D. Quality of life considerations in gynecologic cancer. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006 Nov; 95 Suppl 1:S247-57. PMID: 17161164.
    Citations: 13     Fields:    Translation:Humans
  99. Penson RT, Wenzel LB, Vergote I, Cella D. Quality of Life Considerations in Gynecologic Cancer. Int J Gynaecol Obstet. 2006 Nov; 95 Suppl 1:S247-S257. PMID: 29644666.
    Citations:    Fields:    
  100. Matulonis UA, Campos S, Krasner CN, Duska LR, Penson RT, Falke R, Roche M, Smith LM, Lee H, Seiden MV. Three sequential chemotherapy doublets for the treatment of newly diagnosed advanced müllerian malignancies: the modified triple doublet regimen. Gynecol Oncol. 2006 Nov; 103(2):575-80. PMID: 16806439.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  101. Penson RT, Cannistra SA, Seiden MV, Krasner CN, Matulonis UA, Horowitz NS, Berlin S, Dizon DS, Lee H, Campos SM. Phase II study of carboplatin, paclitaxel and bevacizumab as first line chemotherapy and consolidation for advanced müllerian tumors. J Clin Oncol. 2006 Jun 20; 24(18_suppl):5020. PMID: 27952190.
    Citations:    
  102. Cannistra SA, Matulonis U, Penson R, Wenham R, Armstrong D, Burger RA, Mackey H, Douglas J, Hambleton J, McGuire W. Bevacizumab in patients with advanced platinum-resistant ovarian cancer. J Clin Oncol. 2006 Jun 20; 24(18_suppl):5006. PMID: 27952183.
    Citations:    
  103. Roche M, Matulonis U, Krasner C, Penson R, Horowitz N, Berkenblit A, Findley M, Lee J, Horick N, Seiden MV. Phase II trial of GM-CSF in women with asymptomatic müllerian cancer. J Clin Oncol. 2006 Jun 20; 24(18_suppl):5081. PMID: 27952385.
    Citations:    
  104. Matulonis UA, Kornblith A, Lee H, Bryan J, Gibson C, Wells C, Lee J, Sullivan L, Penson RT. Long-term impact of chemotherapy on early stage ovarian cancer patients. J Clin Oncol. 2006 Jun 20; 24(18_suppl):5024. PMID: 27952136.
    Citations:    
  105. Penson RT, Kyriakou H, Zuckerman D, Chabner BA, Lynch TJ. Teams: communication in multidisciplinary care. Oncologist. 2006 May; 11(5):520-6. PMID: 16720852.
    Citations: 5     Fields:    Translation:Humans
  106. Matulonis UA, Campos S, Duska L, Krasner CN, Atkinson T, Penson RT, Seiden MV, Verrill C, Fuller AF, Goodman A. Phase I/II dose finding study of combination cisplatin and gemcitabine in patients with recurrent cervix cancer. Gynecol Oncol. 2006 Oct; 103(1):160-4. PMID: 16566993.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  107. Abel GA, Penson RT, Joffe S, Schapira L, Chabner BA, Lynch TJ. Direct-to-consumer advertising in oncology. Oncologist. 2006 Feb; 11(2):217-26. PMID: 16476842.
    Citations: 6     Fields:    Translation:Humans
  108. Matulonis UA, Seiden MV, Roche M, Krasner C, Fuller AF, Atkinson T, Kornblith A, Penson R. Long-acting octreotide for the treatment and symptomatic relief of bowel obstruction in advanced ovarian cancer. J Pain Symptom Manage. 2005 Dec; 30(6):563-9. PMID: 16376743.
    Citations: 8     Fields:    Translation:HumansCTClinical Trials
  109. Seiden MV, Gordon AN, Bodurka DC, Matulonis UA, Penson RT, Reed E, Alberts DS, Weems G, Cullen M, McGuire WP. A phase II study of irofulven in women with recurrent and heavily pretreated ovarian cancer. Gynecol Oncol. 2006 Apr; 101(1):55-61. PMID: 16260029.
    Citations: 7     Fields:    Translation:HumansCTClinical Trials
  110. Penson RT, Campos SM, Seiden MV, Krasner C, Fuller AF, Goodman A, Roche M, Willman A, Muzikansky A, Matulonis UA. A phase II study of fixed dose rate gemcitabine in patients with relapsed müllerian tumors. Int J Gynecol Cancer. 2005 Nov-Dec; 15(6):1035-41. PMID: 16343179.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  111. Penson RT, Seiden MV. Topotecan: weighing in when there are many options. Oncologist. 2005 Oct; 10(9):698-700. PMID: 16249349.
    Citations:    Fields:    Translation:Humans
  112. Penson RT, Partridge RA, Rudd P, Seiden MV, Nelson JE, Chabner BA, Lynch TJ. Laughter: the best medicine? Oncologist. 2005 Sep; 10(8):651-60. PMID: 16177290.
    Citations: 7     Fields:    Translation:Humans
  113. Penson RT, Seiden MV, Matulonis UA, Appleman LJ, Fuller AF, Goodman A, Campos SM, Clark JW, Roche M, Eder JP. A phase I clinical trial of continual alternating etoposide and topotecan in refractory solid tumours. Br J Cancer. 2005 Jul 11; 93(1):54-9. PMID: 15986034.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  114. Penson R, Cella D, Wenzel L. Quality of life in ovarian cancer. J Reprod Med. 2005 Jun; 50(6):407-16. PMID: 16050565.
    Citations: 2     Fields:    Translation:Humans
  115. Wolpin BM, Chabner BA, Lynch TJ, Penson RT. Learning to cope: how far is too close? Oncologist. 2005 Jun-Jul; 10(6):449-56. PMID: 15967838.
    Citations: 4     Fields:    Translation:Humans
  116. Penson RT, Krasner CN, Seiden MV, Atkinson T, Kornblith A, Campos S, Klein A, Matulonis U. Long-acting octreotide for the treatment of symptoms of bowel obstruction in advanced ovarian cancer. J Clin Oncol. 2005 Jun; 23(16_suppl):5159. PMID: 27946709.
    Citations:    
  117. Krasner CN, Debernardo RL, Findley M, Penson R, Matulonis U, Atkinson T, Roche M, Seiden MV. Phase II trial of anastrazole in combination with gefitinib in women with asymptomatic mullerian cancer. J Clin Oncol. 2005 Jun; 23(16_suppl):5063. PMID: 27946319.
    Citations:    
  118. Findley MK, Lee H, Seiden MV, Shah MA, Fuller AF, Goodman A, Penson RT. Do more lines of chemotherapy make you live longer? Treatment for ovarian cancer comparing cohorts of patients 1989-90 with 1995-6 in multivariate analysis of survival. J Clin Oncol. 2005 Jun; 23(16_suppl):5062. PMID: 27946318.
    Citations:    
  119. Penson RT, Joel SP, Gloyne A, Clark S, Slevin ML. Morphine analgesia in cancer pain: role of the glucuronides. J Opioid Manag. 2005 May-Jun; 1(2):83-90. PMID: 17319252.
    Citations: 5     Fields:    Translation:Humans
  120. Penson RT, Partridge RA, Shah MA, Giansiracusa D, Chabner BA, Lynch TJ. Fear of death. Oncologist. 2005 Feb; 10(2):160-9. PMID: 15709218.
    Citations: 7     Fields:    Translation:Humans
  121. Lee MS, Gupta N, Penson RT, Loewenstein J, Wepner MS, Seiden MV, Milam AH. Cone damage in patients receiving high-dose irofulven treatment. Arch Ophthalmol. 2005 Jan; 123(1):29-34. PMID: 15642808.
    Citations: 2     Fields:    Translation:HumansCellsCTClinical Trials
  122. Penson RT, Sahani D, Bell DA. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 37-2004. A 52-year-old woman with postmenopausal bleeding and a cystic ovarian mass. N Engl J Med. 2004 Dec 09; 351(24):2531-8. PMID: 15590956.
    Citations:    Fields:    Translation:Humans
  123. Berkenblit A, Seiden MV, Matulonis UA, Penson RT, Krasner CN, Roche M, Mezzetti L, Atkinson T, Cannistra SA. A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer. Gynecol Oncol. 2004 Dec; 95(3):624-31. PMID: 15581974.
    Citations: 11     Fields:    Translation:HumansCTClinical Trials
  124. Lee C, Penson RT. Silence as the speech of care. J Support Oncol. 2004 Sep-Oct; 2(5):455-6. PMID: 15524078.
    Citations:    Fields:    Translation:Humans
  125. Penson RT, Dignan F, Seiden MV, Lee H, Gallagher CJ, Matulonis UA, Olson K, Gibbens I, Gore ME. Attitudes to chemotherapy in patients with ovarian cancer. Gynecol Oncol. 2004 Aug; 94(2):427-35. PMID: 15297184.
    Citations: 2     Fields:    Translation:Humans
  126. Matulonis U, Krasner C, Atkinson T, Penson R. Long-acting octreotide for the treatment of symptoms of bowel obstruction and intermittent obstruction in advanced ovarian cancer. J Clin Oncol. 2004 Jul 15; 22(14_suppl):5148. PMID: 28016806.
    Citations:    
  127. Penson RT, Seiden MV, Campos SM, Krasner CN, Fuller AF, Goodman A, Roche M, Willman A, Muzikansky A, Matulonis UA. A phase II study of fixed dose-rate gemcitabine in patients with relapsed Müllerian tumors. J Clin Oncol. 2004 Jul 15; 22(14_suppl):5151. PMID: 28016790.
    Citations:    
  128. Penson RT, Seiden MV, Goodman A, Fuller AF, Berkowitz RS, Matulonis UA, Krasner C, Lee H, Atkinson T, Campos SM. Phase I trial of escalating doses of topotecan in combination with a fixed dose of pegylated liposomal doxorubicin in women with müllerian malignancies. Gynecol Oncol. 2004 Jun; 93(3):702-7. PMID: 15196868.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  129. Nouriani M, Bahador A, Berek JS, Cheng JP, Chi DS, Cliby WA, Del Priore G, Dodson MK, Duggan BD, Gershenson DM, Lentz SE, Penson RT, Robinson WR, Rodriguez M, Roman LD, Yu MC, Zempolich K, Dubeau L. Detection of residual subclinical ovarian carcinoma after completion of adjuvant chemotherapy. Clin Cancer Res. 2004 Apr 15; 10(8):2681-6. PMID: 15102671.
    Citations:    Fields:    Translation:Humans
  130. Penson RT, Oliva E, Skates SJ, Glyptis T, Fuller AF, Goodman A, Seiden MV. Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples. Gynecol Oncol. 2004 Apr; 93(1):98-106. PMID: 15047220.
    Citations: 39     Fields:    Translation:Humans
  131. Penson RT, Amrein PC. Faith and freedom: leukemia in Jehovah Witness minors. Onkologie. 2004 Apr; 27(2):126-8. PMID: 15138343.
    Citations: 1     Fields:    Translation:Humans
  132. Penson RT, Schapira L, Daniels KJ, Chabner BA, Lynch TJ. Cancer as metaphor. Oncologist. 2004; 9(6):708-16. PMID: 15561814.
    Citations: 7     Fields:    Translation:Humans
  133. Penson RT, Talsania SH, Chabner BA, Lynch TJ. Help me help you: support groups in cancer therapy. Oncologist. 2004; 9(2):217-25. PMID: 15047926.
    Citations: 3     Fields:    Translation:Humans
  134. Penson RT, Daniels KJ, Lynch TJ. Too old to care? Oncologist. 2004; 9(3):343-52. PMID: 15169990.
    Citations: 6     Fields:    Translation:Humans
  135. del Carmen MG, Fuller AF, Matulonis U, Horick NK, Goodman A, Duska LR, Penson R, Campos S, Roche M, Seiden MV. Phase II trial of anastrozole in women with asymptomatic müllerian cancer. Gynecol Oncol. 2003 Dec; 91(3):596-602. PMID: 14675683.
    Citations: 19     Fields:    Translation:HumansCTClinical Trials
  136. Campos SM, Matulonis UA, Penson RT, Lee H, Berkowitz RS, Duska LR, Fuller AF, Wilson KS, Puchalski TA, Supko JG, Seiden MV. Phase II study of liposomal doxorubicin and weekly paclitaxel for recurrent Müllerian tumors. Gynecol Oncol. 2003 Sep; 90(3):610-8. PMID: 13678734.
    Citations: 5     Fields:    Translation:HumansCTClinical Trials
  137. Duan Z, Duan Y, Lamendola DE, Yusuf RZ, Naeem R, Penson RT, Seiden MV. Overexpression of MAGE/GAGE genes in paclitaxel/doxorubicin-resistant human cancer cell lines. Clin Cancer Res. 2003 Jul; 9(7):2778-85. PMID: 12855658.
    Citations: 45     Fields:    Translation:HumansCells
  138. Yusuf RZ, Duan Z, Lamendola DE, Penson RT, Seiden MV. Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr Cancer Drug Targets. 2003 Feb; 3(1):1-19. PMID: 12570657.
    Citations: 67     Fields:    Translation:Humans
  139. Dias L, Chabner BA, Lynch TJ, Penson RT. Breaking bad news: a patient's perspective. Oncologist. 2003; 8(6):587-96. PMID: 14657537.
    Citations: 10     Fields:    Translation:Humans
  140. Knuti KA, Wharton RH, Wharton KL, Chabner BA, Lynch TJ, Penson RT. Living as a cancer surpriser: a doctor tells his story. Oncologist. 2003; 8(1):108-22. PMID: 12604737.
    Citations: 4     Fields:    Translation:Humans
  141. Penson RT, Nunn C, Younger J, Schaeffer NJ, Chabner BA, Fricchione GL, Quinn TE, Lynch TJ. Trust violated: analgesics for addicts. Oncologist. 2003; 8(2):199-209. PMID: 12697944.
    Citations:    Fields:    Translation:Humans
  142. Lamendola DE, Duan Z, Penson RT, Oliva E, Seiden MV. beta tubulin mutations are rare in human ovarian carcinoma. Anticancer Res. 2003 Jan-Feb; 23(1B):681-6. PMID: 12680167.
    Citations: 6     Fields:    Translation:Humans
  143. Penson RT, Fergus LA, Haston RJ, Clark JR, Demotses A, O'Connell JJ, Chabner BA, Lynch TJ. The Kenneth B. Schwartz Center at Massachusetts General Hospital hematology-oncology department: hope for the homeless. Oncologist. 2003; 8(5):488-95. PMID: 14530502.
    Citations:    Fields:    Translation:Humans
  144. Duan Z, Lamendola DE, Yusuf RZ, Penson RT, Preffer FI, Seiden MV. Overexpression of human phosphoglycerate kinase 1 (PGK1) induces a multidrug resistance phenotype. Anticancer Res. 2002 Jul-Aug; 22(4):1933-41. PMID: 12174867.
    Citations: 18     Fields:    Translation:Humans
  145. Duska LR, Garrett A, Eltabbakh GH, Oliva E, Penson R, Fuller AF. Paclitaxel and platinum chemotherapy for malignant mixed müllerian tumors of the ovary. Gynecol Oncol. 2002 Jun; 85(3):459-63. PMID: 12051874.
    Citations: 12     Fields:    Translation:Humans
  146. Penson RT, Joel SP, Roberts M, Gloyne A, Beckwith S, Slevin ML. The bioavailability and pharmacokinetics of subcutaneous, nebulized and oral morphine-6-glucuronide. Br J Clin Pharmacol. 2002 Apr; 53(4):347-54. PMID: 11966664.
    Citations: 6     Fields:    Translation:HumansCTClinical Trials
  147. Duan Z, Lamendola DE, Penson RT, Kronish KM, Seiden MV. Overexpression of IL-6 but not IL-8 increases paclitaxel resistance of U-2OS human osteosarcoma cells. Cytokine. 2002 Mar 07; 17(5):234-42. PMID: 12027404.
    Citations: 18     Fields:    Translation:HumansCells
  148. Penson RT, Green KM, Chabner BA, Lynch TJ. When does the responsibility of our care end: bereavement. Oncologist. 2002; 7(3):251-8. PMID: 12065799.
    Citations: 7     Fields:    Translation:Humans
  149. Penson RT, Benson RC, Parles K, Chabner BA, Lynch TJ. Virtual connections: Internet health care. Oncologist. 2002; 7(6):555-68. PMID: 12490743.
    Citations: 5     Fields:    Translation:Humans
  150. Knuti KA, Amrein PC, Chabner BA, Lynch TJ, Penson RT. Faith, identity, and leukemia: when blood products are not an option. Oncologist. 2002; 7(4):371-80. PMID: 12185299.
    Citations: 1     Fields:    Translation:Humans
  151. Penson RT, Rauch PK, McAfee SL, Cashavelly BJ, Clair-Hayes K, Dahlin C, Green KM, Chabner BA, Lynch TJ. Between parent and child: negotiating cancer treatment in adolescents. Oncologist. 2002; 7(2):154-62. PMID: 11961199.
    Citations: 3     Fields:    Translation:Humans
  152. Penson RT, Joel SP, Clark S, Gloyne A, Slevin ML. Limited phase I study of morphine-3-glucuronide. J Pharm Sci. 2001 Nov; 90(11):1810-6. PMID: 11745739.
    Citations: 15     Fields:    Translation:HumansAnimalsCTClinical Trials
  153. Penson RT, Supko JG, Seiden MV, Fuller AF, Berkowitz RS, Goodman A, Campos SM, MacNeill KM, Cook S, Matulonis UA. A Phase I-II study of 96-hour infusional topotecan and paclitaxel for patients with recurrent Müllerian tumors. Cancer. 2001 Sep 01; 92(5):1156-67. PMID: 11571729.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  154. Penson RT, Fuller AF. Nodal metastasis is highly consistent in squamous cell carcinoma of the vulva. J Clin Oncol. 2001 May 15; 19(10):2767-8. PMID: 11352972.
    Citations:    Fields:    Translation:Humans
  155. Campos SM, Penson RT, Mays AR, Berkowitz RS, Fuller AF, Goodman A, Matulonis UA, Muzikansky A, Seiden MV. The clinical utility of liposomal doxorubicin in recurrent ovarian cancer. Gynecol Oncol. 2001 May; 81(2):206-12. PMID: 11330951.
    Citations: 19     Fields:    Translation:Humans
  156. Penson RT, Fuller AF. Nodal metastasis is highly consistent in squamous cell carcinoma of the vulva. J Clin Oncol. 2001 Apr 15; 19(8):2364-5. PMID: 11304789.
    Citations:    Fields:    Translation:Humans
  157. Penson RT, Castro CM, Seiden MV, Chabner BA, Lynch TJ. Complementary, alternative, integrative, or unconventional medicine? Oncologist. 2001; 6(5):463-73. PMID: 11675526.
    Citations: 7     Fields:    Translation:Humans
  158. Penson RT, Yusuf RZ, Chabner BA, Lafrancesca JP, McElhinny M, Axelrad AS, Lynch TJ. Losing God. Oncologist. 2001; 6(3):286-97. PMID: 11423676.
    Citations: 2     Fields:    Translation:Humans
  159. Penson RT, Seiden MV, Chabner BA, Lynch TJ. Caring for colleagues. Oncologist. 2001; 6(2):197-204. PMID: 11306731.
    Citations:    Fields:    Translation:Humans
  160. Mulatero CW, Penson RT, Papamichael D, Gower NH, Evans M, Rudd RM. A phase II study of combined intravenous and subcutaneous interleukin-2 in malignant pleural mesothelioma. Lung Cancer. 2001 Jan; 31(1):67-72. PMID: 11162868.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  161. Penson RT, Svendsen SS, Chabner BA, Lynch TJ, Levinson W. Medical mistakes: a workshop on personal perspectives. Oncologist. 2001; 6(1):92-9. PMID: 11161232.
    Citations: 5     Fields:    Translation:Humans
  162. Penson RT, Joel SP, Bakhshi K, Clark SJ, Langford RM, Slevin ML. Randomized placebo-controlled trial of the activity of the morphine glucuronides. Clin Pharmacol Ther. 2000 Dec; 68(6):667-76. PMID: 11180027.
    Citations: 23     Fields:    Translation:HumansCTClinical Trials
  163. Feller AJ, Duan Z, Penson R, Toh HC, Seiden MV. TRAG-3, a novel cancer/testis antigen, is overexpressed in the majority of melanoma cell lines and malignant melanoma. Anticancer Res. 2000 Nov-Dec; 20(6B):4147-51. PMID: 11205240.
    Citations: 4     Fields:    Translation:HumansCells
  164. Cook S, Penson R, Duska L, Nikrui N, Goodman A, Fuller A, Seiden M. Efficacy and hematologic toxicity of salvage chemotherapy following stem cell-supported high-dose chemotherapy in women with recurrent ovarian cancer. Gynecol Oncol. 2000 Apr; 77(1):48-54. PMID: 10739690.
    Citations: 2     Fields:    Translation:Humans
  165. Penson RT, Dignan FL, Canellos GP, Picard CL, Lynch TJ. Burnout: caring for the caregivers. Oncologist. 2000; 5(5):425-34. PMID: 11040279.
    Citations: 11     Fields:    Translation:Humans
  166. Penson RT, Gallagher J, Gioiella ME, Wallace M, Borden K, Duska LA, Talcott JA, McGovern FJ, Appleman LJ, Chabner BA, Lynch TJ. Sexuality and cancer: conversation comfort zone. Oncologist. 2000; 5(4):336-44. PMID: 10965002.
    Citations: 4     Fields:    Translation:Humans
  167. Penson RT, Kronish K, Duan Z, Feller AJ, Stark P, Cook SE, Duska LR, Fuller AF, Goodman AK, Nikrui N, MacNeill KM, Matulonis UA, Preffer FI, Seiden MV. Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFalpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel. Int J Gynecol Cancer. 2000 Jan; 10(1):33-41. PMID: 11240649.
    Citations: 42     Fields:    
  168. Penson RT, Seiden MV, Shannon KM, Lubratovich ML, Roche M, Chabner BA, Lynch TJ. Communicating genetic risk: pros, cons, and counsel. Oncologist. 2000; 5(2):152-61. PMID: 10794806.
    Citations: 1     Fields:    Translation:Humans
  169. Krakauer EL, Penson RT, Truog RD, King LA, Chabner BA, Lynch TJ. Sedation for intractable distress of a dying patient: acute palliative care and the principle of double effect. Oncologist. 2000; 5(1):53-62. PMID: 10706650.
    Citations: 18     Fields:    Translation:Humans
  170. Duan Z, Feller AJ, Penson RT, Chabner BA, Seiden MV. Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype. Clin Cancer Res. 1999 Nov; 5(11):3445-53. PMID: 10589757.
    Citations: 33     Fields:    Translation:HumansCells
  171. Penson RT, Skates SJ, Fuller AJ, Seiden MV. Clinical course of stage IV epithelial ovarian cancer. J Clin Oncol. 1999 Oct; 17(10):3361-2. PMID: 10506641.
    Citations: 2     Fields:    Translation:Humans
  172. Duska LR, Penson R, Supko JG, Finkelstein DM, Makastorsis T, Gallagher J, Borden K, Goodman A, Fuller AF, Nikrui N, Seiden MV. A Phase I study of continuous infusion doxorubicin and paclitaxel chemotherapy with granulocyte colony-stimulating factor for relapsed epithelial ovarian cancer. Clin Cancer Res. 1999 Jun; 5(6):1299-305. PMID: 10389912.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  173. Penson RT, Seiden MV. Progress in gynecologic oncology. Oncologist. 1999; 4(4):293-8. PMID: 10476540.
    Citations:    Fields:    Translation:HumansPHPublic Health
  174. O'Shea EM, Penson RT, Stern TA, Younger J, Chabner BA, Lynch TJ. A staff dialogue on do not resuscitate orders: psychosocial issues faced by patients, their families, and caregivers. Oncologist. 1999; 4(3):256-62. PMID: 10394593.
    Citations:    Fields:    Translation:Humans
  175. O'Shea EM, Lintz KC, Penson RT, Seiden MV, Chabner BA, Lynch TJ. A staff dialogue on caring for a cancer patient who commits suicide: psychosocial issues faced by patients, their families, and caregivers. Oncologist. 1999; 4(2):122-7. PMID: 10337382.
    Citations:    Fields:    Translation:Humans
  176. Lintz KC, Penson RT, Cassem N, Harmon DC, Chabner BA, Lynch TJ. A staff dialogue on aggressive palliative treatment demanded by a terminally ill patient: psychosocial issues faced by patients, their families, and caregivers. Oncologist. 1999; 4(1):70-6. PMID: 10337374.
    Citations: 1     Fields:    Translation:Humans
  177. Ryan DP, Penson RT, Ahmed S, Chabner BA, Lynch TJ. Reality testing in cancer treatment: the phase I trial of endostatin. Oncologist. 1999; 4(6):501-8. PMID: 10631694.
    Citations: 2     Fields:    Translation:Humans
  178. Dedier J, Penson R, Williams W, Lynch T. Race, ethnicity, and the patient-caregiver relationship. Oncologist. 1999; 4(4):325-31. PMID: 10476544.
    Citations: 5     Fields:    Translation:Humans
  179. Goodman A, Penson RT, Blatman R, McIntyre J, Gioiella ME, Chabner BA, Lynch TJ. A staff dialogue on a socially distanced patient: psychosocial issues faced by patients, their families, and caregivers. Oncologist. 1999; 4(5):417-24. PMID: 10551558.
    Citations:    Fields:    Translation:Humans
  180. Papamichael D, Seymour MT, Penson RT, Wilson P, Gallagher CJ, Besser GM, Slevin ML. Double modulation of 5-fluorouracil with interferon alpha-2a and high-dose leucovorin in advanced neuroendocrine tumours. Eur J Cancer. 1998 Dec; 34(13):2133-4. PMID: 10070325.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  181. Joel S, O'Byrne K, Penson R, Papamichael D, Higgins A, Robertshaw H, Rudd R, Talbot D, Slevin M. A randomised, concentration-controlled, comparison of standard (5-day) vs. prolonged (15-day) infusions of etoposide phosphate in small-cell lung cancer. Ann Oncol. 1998 Nov; 9(11):1205-11. PMID: 9862051.
    Citations: 7     Fields:    Translation:HumansCTClinical Trials
  182. Penson RT, Shannon KE, Sharpless NE, Seiden MV. Ovarian cancer: an update on genetics and therapy. Compr Ther. 1998 Oct; 24(10):477-87. PMID: 9801846.
    Citations: 4     Fields:    Translation:Humans
  183. Lintz KC, Penson RT, Chabner BA, Lynch TJ. Schwartz Center Rounds. A Staff Dialogue on Caring for an Intensely Spiritual Patient: Psychosocial Issues Faced By Patients, Their Families, and Caregivers. Oncologist. 1998; 3(6):439-445. PMID: 10388136.
    Citations:    Fields:    
  184. Lintz KC, Penson RT, Chabner BA, Mack S, Lynch TJ. Schwartz Center Rounds. A Staff Dialogue on Phase I Trials: Psychosocial Issues Faced by Patients, Their Families, and Caregivers. Oncologist. 1998; 3(5):357-364. PMID: 10388126.
    Citations: 1     Fields:    
  185. Penson R, Gallagher C, Hooi Y, Soosay G, Lucas S. Metastatic tufted angioma. Int J STD AIDS. 1997 Aug; 8(8):530-1. PMID: 9259505.
    Citations:    Fields:    Translation:Humans
  186. Penson RT, Rudd RM. Poor recruitment to lung cancer trials. BMJ. 1997 Mar 29; 314(7085):974-5. PMID: 9099129.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  187. Penson RT, Rudd RM. Commentary: octreotide and hypertrophic pulmonary osteoarthropathy. Thorax. 1997 Mar; 52(3):297-8. PMID: 9093353.
    Citations: 2     Fields:    Translation:Humans
  188. Mainwaring PN, Nicolson MC, Hickish T, Penson R, Joel S, Slevin M, Smith IE. Continuous infusional topotecan in advanced breast and non-small-cell lung cancer: no evidence of increased efficacy. Br J Cancer. 1997; 76(12):1636-9. PMID: 9413954.
    Citations: 5     Fields:    Translation:HumansCTClinical Trials
  189. Gore ME, Rustin G, Slevin M, Gallagher C, Penson R, Osborne R, Ledermann J, Cameron T, Thompson JM. Single-agent paclitaxel in patients with previously untreated stage IV epithelial ovarian cancer. London Gynaecological Oncology and North Thames Gynaecological Oncology Groups. Br J Cancer. 1997; 75(5):710-4. PMID: 9043029.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  190. Joel SP, Ellis P, O'Byrne K, Papamichael D, Hall M, Penson R, Nicholls S, O'Donnell C, Constantinou A, Woodhull J, Nicholson M, Smith I, Talbot D, Slevin M. Therapeutic monitoring of continuous infusion etoposide in small-cell lung cancer. J Clin Oncol. 1996 Jun; 14(6):1903-12. PMID: 8656259.
    Citations: 10     Fields:    Translation:HumansCTClinical Trials
  191. Penson RT, Doyal L, Slevin ML. Ethical issues in cancer treatment. Br J Urol. 1995 Nov; 76 Suppl 2:37-40. PMID: 8535752.
    Citations:    Fields:    
  192. Robinson AJ, Taylor AM, Penson RT, Gupta RK, Slevin ML. Phantom pancreatic tumours. Br J Hosp Med. 1995 Aug 16-Sep 5; 54(4):170-1. PMID: 7582370.
    Citations:    Fields:    Translation:Humans
  193. Highley MS, Parnis FX, Trotter GA, Houston SJ, Penson RT, Harper PG, Mason RC. Combination chemotherapy with epirubicin, cisplatin and 5-fluorouracil for the palliation of advanced gastric and oesophageal adenocarcinoma. Br J Surg. 1994 Dec; 81(12):1763-5. PMID: 7530150.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Penson's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (525)
Explore
_
Co-Authors (91)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.